However, a number of large clinical trials in recent years have demonstrated the potent cardiorenal protective effects of SGLT2 inhibitors, and interestingly, their protective effects have been observed in both patients with and those without diabetes mellitus (3–8). This evidence concerns the gene SLC5A2 and diabetes mellitus.